[go: up one dir, main page]

UY26112A1 - Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona - Google Patents

Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona

Info

Publication number
UY26112A1
UY26112A1 UY26112A UY26112A UY26112A1 UY 26112 A1 UY26112 A1 UY 26112A1 UY 26112 A UY26112 A UY 26112A UY 26112 A UY26112 A UY 26112A UY 26112 A1 UY26112 A1 UY 26112A1
Authority
UY
Uruguay
Prior art keywords
hydrochloride
thiazolidine
amino
methyl
piridil
Prior art date
Application number
UY26112A
Other languages
English (en)
Inventor
Robert Gordon Giles
Michael John Sasse
Paul David James Blackler
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of UY26112A1 publication Critical patent/UY26112A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Dihidrato de hidrocloruro de 5- [4-[2-(N-metil-N-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona, caracterizado porque: (i) proporciona un espectro infrarrojo que contiene picos a 3.392, 2.739, 1-751, 1.325 y 713 cm-1; y/o (ii) proporciona un modelo de dirección de rayos X a través de polvo (XRPD) que contiene picos a 9,1, 12,0, 15,7, 16,3 y 19,8s20 tita. También es incluido un procedimiento para su preparación, caracterizado porque el dihidrato es tratado con una fuente adecuada de iones contrarios de hidrocloruro y una cantidad apropiada de agua para que se forme el hidrato de hidrocloruro; y después de esto, se recupera el compuesto requerido. Así como también una composición farmacéutica que comprende una cantidad eficaz y no tóxica de un hidrato, y un vehículo farmcéuticamente aceptable para su utilización como una sustancia terapéutica activa, por ejemplo para el tratamiento y/o profilaxis de diabetes mellitus, condiciones asociadas con diabetes mellitus y ciertas complicaciones de las mismas.
UY26112A 1999-04-20 2000-04-19 Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona UY26112A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9909041.7A GB9909041D0 (en) 1999-04-20 1999-04-20 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
UY26112A1 true UY26112A1 (es) 2000-12-29

Family

ID=10851901

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26112A UY26112A1 (es) 1999-04-20 2000-04-19 Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona

Country Status (42)

Country Link
EP (2) EP1173436B1 (es)
JP (2) JP4283449B2 (es)
KR (1) KR100601244B1 (es)
CN (2) CN101134756A (es)
AP (1) AP1562A (es)
AR (2) AR023566A1 (es)
AT (1) ATE268770T1 (es)
AU (2) AU4130900A (es)
BG (1) BG65864B1 (es)
BR (1) BR0009897A (es)
CA (1) CA2382036A1 (es)
CO (1) CO5170422A1 (es)
CZ (1) CZ300653B6 (es)
DE (1) DE60011419T2 (es)
DK (1) DK1173436T3 (es)
DZ (1) DZ3162A1 (es)
EA (1) EA004232B1 (es)
EG (1) EG24063A (es)
ES (1) ES2218146T3 (es)
GB (1) GB9909041D0 (es)
HK (1) HK1045151B (es)
HR (1) HRP20010770B1 (es)
HU (1) HUP0200865A3 (es)
IL (1) IL146078A0 (es)
MA (1) MA26783A1 (es)
MX (1) MXPA01010696A (es)
MY (1) MY126034A (es)
NO (1) NO320609B1 (es)
NZ (1) NZ515166A (es)
OA (1) OA11866A (es)
PE (1) PE20010050A1 (es)
PL (1) PL351135A1 (es)
PT (1) PT1173436E (es)
RS (1) RS50136B (es)
SI (1) SI1173436T1 (es)
SK (1) SK284991B6 (es)
TR (1) TR200103040T2 (es)
TW (1) TWI277616B (es)
UA (1) UA71615C2 (es)
UY (1) UY26112A1 (es)
WO (1) WO2000063205A2 (es)
ZA (1) ZA200108720B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
PT1448559E (pt) * 2001-11-21 2007-03-30 Smithkline Beecham Plc Benzenossulfonato de 5-(4-(2-(n-metil-n-(2-piridil)amino)etoxi)benzil)tiazolidina-2, 4-diona; processo para a sua preparação; seus polimorfos i, ii e iii; e sua utilização como ingrediente farmacêutico activo
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
CZ296472B6 (cs) * 2004-07-27 2006-03-15 Zentiva, A. S Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP1842850A1 (en) * 2006-03-23 2007-10-10 Sandoz AG Rosiglitazone hydrochloride hemihydrate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical

Also Published As

Publication number Publication date
EP1173436A2 (en) 2002-01-23
SK284991B6 (sk) 2006-04-06
GB9909041D0 (en) 1999-06-16
EA004232B1 (ru) 2004-02-26
EA200101101A1 (ru) 2002-04-25
BG65864B1 (bg) 2010-03-31
HRP20010770A2 (en) 2002-10-31
AP2001002331A0 (en) 2000-04-19
JP2009143954A (ja) 2009-07-02
ES2218146T3 (es) 2004-11-16
UA71615C2 (uk) 2004-12-15
SI1173436T1 (en) 2004-12-31
AU4130900A (en) 2000-11-02
RS50136B (sr) 2009-03-25
DE60011419T2 (de) 2005-06-16
MY126034A (en) 2006-09-29
AR023562A1 (es) 2002-09-04
OA11866A (en) 2006-03-02
TR200103040T2 (tr) 2002-04-22
DK1173436T3 (da) 2004-09-27
KR100601244B1 (ko) 2006-07-19
HUP0200865A3 (en) 2005-04-28
DE60011419D1 (de) 2004-07-15
PE20010050A1 (es) 2001-03-10
HK1045151A1 (en) 2002-11-15
CN101134756A (zh) 2008-03-05
ZA200108720B (en) 2002-11-28
MXPA01010696A (es) 2002-06-04
PT1173436E (pt) 2004-10-29
CN1327447A (zh) 2001-12-19
BG106112A (bg) 2002-05-31
AU2755202A (en) 2002-05-16
DZ3162A1 (fr) 2000-10-26
SK14902001A3 (sk) 2002-02-05
TWI277616B (en) 2007-04-01
AU765911B2 (en) 2003-10-02
WO2000063205A2 (en) 2000-10-26
HK1045151B (zh) 2005-03-18
AP1562A (en) 2006-02-01
WO2000063205A3 (en) 2001-01-25
CO5170422A1 (es) 2002-06-27
HUP0200865A2 (en) 2002-08-28
ATE268770T1 (de) 2004-06-15
PL351135A1 (en) 2003-03-24
CA2382036A1 (en) 2000-10-26
IL146078A0 (en) 2002-07-25
NO20015104D0 (no) 2001-10-19
JP4283449B2 (ja) 2009-06-24
KR20010110791A (ko) 2001-12-13
AR023566A1 (es) 2002-09-04
EP1411055A1 (en) 2004-04-21
NO20015104L (no) 2001-12-19
MA26783A1 (fr) 2004-12-20
CZ300653B6 (cs) 2009-07-08
EG24063A (en) 2008-05-08
YU81501A (sh) 2004-07-15
HRP20010770B1 (en) 2005-06-30
JP2002542242A (ja) 2002-12-10
EP1173436B1 (en) 2004-06-09
BR0009897A (pt) 2002-04-16
NZ515166A (en) 2004-02-27
NO320609B1 (no) 2005-12-27
CZ20013759A3 (cs) 2002-05-15

Similar Documents

Publication Publication Date Title
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
AR030920A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
ATE339956T1 (de) Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
EP1078923A3 (en) Process for the preparation of benzothiophene derivatives
WO2003029169A3 (en) Hydroxypropylamines
RU2001131722A (ru) 5-[4-(6-Метокси-1-метил-1Н-бензимидазол-2-илметокси)бензил]-тиазолидин-2,4 -ди он гидрохлорид, обладающий гипогликемической активностью
UY26112A1 (es) Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
BR0114196A (pt) Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
AR017430A1 (es) Un hidrato de la sal del acido maleico de la 5[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona, un proceso para su preparacion,composicion farmaceutica que lo contiene y uso del mismo para la fabricacion de un medicamento
JP2002508372A5 (es)
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
HUP0003260A2 (hu) Gyógyszerkészítmény diabetes kezelésére rosziglitazonnal és inzulinnal
PE20010047A1 (es) Monohidrato de hidrocloruro de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
YU16303A (sh) Tartaratne soli derivata tiazolidindiona
AU2002343052A1 (en) Rosiglitazone edisylates and their use as antidiabetics
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
HK1057751A1 (en) A thiazolidinedione derivative and its use as antidiabetic
NZ524933A (en) Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20100712

VENC Patent expired

Effective date: 20200419